This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SP-01A
Description: SP-01A dose-dependently reduces the levels of the rate-limiting enzyme HMG-CoA reductase mRNA, leading to decreased intracellular cholesterol and corticosteroid biosynthesis. Reduction of intracellular cholesterol subsequently interferes with the ability of membrane microdomains or lipid rafts to organize cellular receptors and coreceptors, which optimally interferes with the viral envelope. As a result, viral envelope glycoproteins never undergo the conformational changes required to form the molecular scaffold presumed responsible for bringing the viral membrane close to the target cell membrane and triggering fusion.
Deal Structure: In March 2007, Samaritan Pharmaceuticals and Pharmaplaz, Ltd., a private Irish healthcare company, entered a collaboration to develop and commercialize SP-01A. Under the terms of the agreement, Samaritan is to receive $10 million upfront in two tranches. Pharmaplaz will be responsible for clinical development, clinical trial costs and manufacturing. Upon successful commercialization, Samaritan and Pharmaplaz will co-market SP-01A and will share 50-50 in its revenue royalty stream.
Partners: Samaritan Pharmaceuticals
Pink Sheet Samaritan fusion inhibitor progress
Additional information available to subscribers only: